Evidence map›Paper›PMID 26622172›Full record

ArticleClinical interventions in aging2015

Real-world evaluation of compliance and preference in Alzheimer's disease treatment.

Ming-Chyi Pai, Hany Aref, Nazem Bassil, Nagaendran Kandiah, Jae-Hong Lee, A V Srinivasan, Shelley diTommaso, Ozgur Yuksel

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical interventions in aging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Transdermal Drug Delivery Systems and Their Use in Obesity Treatment.International journal of molecular sciences · 2021
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 7 countries.

Ming-Chyi PaiDivision of Behavioral Neurology, Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan City, Taiwan ; Alzheimer's Disease Research Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan City, Taiwan.
Hany ArefDepartment of Neurology, Ain Shams University, Cairo, Egypt.
Nazem BassilSaint Georges Hospital Medical Center, Balamand University, Beirut, Lebanon.
Nagaendran KandiahDepartment of Neurology, National Neuroscience Institute, Tan Tock Seng Hospital, Singapore.
Jae-Hong LeeDepartment of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, South Korea.
A V SrinivasanThe Tamil Nadu Dr MGR Medical University, Chennai, Tamil Nadu, India.
Shelley diTommasoNovartis Pharma AG, Postfach, Basel, Switzerland.
Ozgur YukselNovartis Pharma AG, Postfach, Basel, Switzerland.
Novartis (Switzerland) · CHAin Shams University · EGAsan Medical Center · KRNational Cheng Kung University Hospital · TWNational Neuroscience Institute · SGTamil Nadu Dr. M.G.R. Medical University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRivastigmine transdermal patch has shown higher caregiver satisfaction and greater preference than oral formulation in patients with Alzheimer's disease. However, there is limited literature available related to caregiver preference or treatment compliance in real-world clinical settings. To date, no such data are available from Asia and the Middle East, which account for a sizeable proportion of patients with Alzheimer's disease. The objective of this study was to evaluate treatment preference and compliance with oral and transdermal medications in daily clinical practice in an ethnically diverse patient population from Asia and the Middle East with mild-to-moderate Alzheimer's disease. PATIENTS AND

methodsRECAP (Real-world Evaluation of Compliance And Preference in the treatment of Alzheimer's disease) was a 24-week, multicenter, prospective, noninterventional study. Two treatment cohorts were observed during the study: oral (cholinesterase inhibitors or memantine) and transdermal (rivastigmine patch). Caregiver preference, physician preference, and patient compliance were evaluated at week 24.

resultsA total of 978 of 1,931 enrolled patients (mean age: 72.8 years; 50.5% female) were in the transdermal cohort. For patients with exposure to both oral and transdermal monotherapy (n=330), a significant caregivers' preference for the transdermal monotherapy was observed (82.7%; P<0.0001). Of the 89 participating physicians, 71 indicated preference for transdermal monotherapy. Patient compliance was also significantly higher for transdermal than oral monotherapy (P<0.0001).

conclusionOur study showed higher caregiver and physician preference and greater patient compliance with transdermal monotherapy in daily practice.

Indexed as

Drug MonitoringAdministration, CutaneousAdministration, OralAgedAged, 80 and overAlzheimer DiseaseAsiaAttitude of Health PersonnelCaregiversCholinesterase InhibitorsDonepezilFemaleGalantamineHumansIndansMaleCholinesterase InhibitorsDonepezilGalantamineIndansMemantinePiperidinesRivastigmineAlzheimer’s diseasecholinesterase inhibitorsobservational studypatient compliancerivastigminetransdermal patch

Identifiers

PMID26622172
PMCPMC4639476
OpenAlexW1934622602

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.